医药研究:中性评级与目标价分析.pdfVIP

  • 0
  • 0
  • 约4.8万字
  • 约 12页
  • 2025-10-22 发布于北京
  • 举报

24April2014

Americas/UnitedStates

EquityResearch

Biotechnology

TheMedicinesCompany(MDCO)

RatingNEUTRAL*

Price(24Apr14,US$)26.05EARNINGS

Targetprice(US$)28.00¹

52-weekpricerange40.39-24.02

Marketcap.(US$m)1,684.80StrongUSAngiomax;NewHospitalProduct

Enterprisevalue(US$m)1,499.94

*StockratingsarerelativetothecoverageuniverseineachAcquired;StillCautious

analystsoreachteamsrespectivesector.

¹Targetpriceisfor12months.WhilecommercialresultsforQ1wererelativelysolid–terthan

文档评论(0)

1亿VIP精品文档

相关文档